PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16104901-2 2005 The secondary goals of ASCENT are to evaluate the effect of DN-101 combined with docetaxel on PSA progression-free survival, tumour response rate in measurable disease, tumour progression-free survival, skeletal morbidity-free survival, clinical progression-free survival, and overall survival, and to examine the safety and tolerability of DN-101 combined with docetaxel. Calcitriol 60-66 kallikrein related peptidase 3 Homo sapiens 94-97 16779800-12 2006 CONCLUSIONS: The novel combination of dexamethasone, calcitriol, and carboplatin for patients with HRPC produced a PSA response in 13 of 34 patients and had an acceptable side-effect profile. Calcitriol 53-63 kallikrein related peptidase 3 Homo sapiens 115-118 16675575-0 2006 Effect of calcitriol on prostate-specific antigen in vitro and in humans. Calcitriol 10-20 kallikrein related peptidase 3 Homo sapiens 24-49 16675575-2 2006 Measurement of its antineoplastic activity in prostate cancer clinical trials may be complicated by effects of calcitriol on prostate-specific antigen (PSA) production. Calcitriol 111-121 kallikrein related peptidase 3 Homo sapiens 125-156 16675575-11 2006 CONCLUSIONS: At clinically achievable concentrations, calcitriol inhibits growth and induces AR and PSA expression in LNCaP cells. Calcitriol 54-64 kallikrein related peptidase 3 Homo sapiens 100-103 17308271-7 2007 Overall, PSA response rates were 63% (DN-101) and 52% (placebo), P = .07. Calcitriol 38-44 kallikrein related peptidase 3 Homo sapiens 9-12 9231780-1 1997 We and others have recently shown that 1alpha,25-dihydroxyvitamin D3 [1,25-(OH)2D3] significantly inhibits cell proliferation and increases secretion of prostate-specific antigen (PSA) in LNCaP cells, an androgen-responsive human prostate cancer cell line. Calcitriol 39-70 kallikrein related peptidase 3 Homo sapiens 153-184 12599228-0 2003 High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Calcitriol 22-32 kallikrein related peptidase 3 Homo sapiens 59-62 12899524-14 2003 Small clinical trials have shown that 1,25(OH)2D3 can slow the rate of prostate specific antigen (PSA) rise in PCa patients, demonstrating proof of concept that 1,25(OH)2D3 or its analogs will be clinically effective in PCa therapy. Calcitriol 38-49 kallikrein related peptidase 3 Homo sapiens 71-96 12899524-14 2003 Small clinical trials have shown that 1,25(OH)2D3 can slow the rate of prostate specific antigen (PSA) rise in PCa patients, demonstrating proof of concept that 1,25(OH)2D3 or its analogs will be clinically effective in PCa therapy. Calcitriol 161-172 kallikrein related peptidase 3 Homo sapiens 71-96 15749627-2 2005 Calcitriol has been shown to prolong the doubling time of PSA in this context, but near-toxic doses are required. Calcitriol 0-10 kallikrein related peptidase 3 Homo sapiens 58-61 11685729-10 2001 All 5 patients who had completed 8 weeks of calcitriol/docetaxel treatment achieved prostate-specific antigen (PSA) reductions of > or =50%. Calcitriol 44-54 kallikrein related peptidase 3 Homo sapiens 84-115 9598513-2 1998 Our hypothesis was that calcitriol therapy slows the rate of rise of prostate specific antigen (PSA) compared with the pretreatment rate. Calcitriol 24-34 kallikrein related peptidase 3 Homo sapiens 69-94 9598513-2 1998 Our hypothesis was that calcitriol therapy slows the rate of rise of prostate specific antigen (PSA) compared with the pretreatment rate. Calcitriol 24-34 kallikrein related peptidase 3 Homo sapiens 96-99 9598513-8 1998 RESULTS: As determined by multiple regression analysis, the rate of PSA rise during versus before calcitriol therapy significantly decreased in 6 of 7 patients, while in the remaining man a deceleration in the rate of PSA rise did not reach statistical significance. Calcitriol 98-108 kallikrein related peptidase 3 Homo sapiens 68-71 9598513-12 1998 CONCLUSIONS: This pilot study provides preliminary evidence that calcitriol effectively slows the rate of PSA rise in select cases, although dose dependent calciuric side effects limit its clinical usefulness. Calcitriol 65-75 kallikrein related peptidase 3 Homo sapiens 106-109 9231780-1 1997 We and others have recently shown that 1alpha,25-dihydroxyvitamin D3 [1,25-(OH)2D3] significantly inhibits cell proliferation and increases secretion of prostate-specific antigen (PSA) in LNCaP cells, an androgen-responsive human prostate cancer cell line. Calcitriol 70-82 kallikrein related peptidase 3 Homo sapiens 153-184 9231780-4 1997 1,25-(OH)2D3-treated cells showed a 5-fold increase in PSA secretion, similar to the increase seen in dihydrotestosterone (DHT)-treated cells. Calcitriol 0-12 kallikrein related peptidase 3 Homo sapiens 55-58 9231780-5 1997 In combination, 1,25-(OH)2D3 and DHT synergistically enhanced PSA secretion 22-fold. Calcitriol 16-28 kallikrein related peptidase 3 Homo sapiens 62-65 9231780-7 1997 Under these conditions, 1,25-(OH)2D3 and DHT together stimulated PSA secretion up to 50-fold over the untreated control. Calcitriol 24-36 kallikrein related peptidase 3 Homo sapiens 65-68 9231780-11 1997 In conclusion, these results demonstrate that the antiproliferative and PSA induction activities of 1,25-(OH)2D3 in LNCaP cells are dependent upon androgen action and that AR up-regulation by 1,25-(OH)2D3 likely contributes to the synergistic actions of 1,25-(OH)2D3 and DHT in these cells. Calcitriol 100-112 kallikrein related peptidase 3 Homo sapiens 72-75 8827086-8 1996 Further comparative studies indicate that upregulation of PSA is common to various differentiation inducers, including all-trans-retinoic acid, 1,25-dihydroxyvitamin D3, and butyrate but is not induced by other antitumor agents of clinical interest such as suramin. Calcitriol 144-168 kallikrein related peptidase 3 Homo sapiens 58-61 7682937-10 1993 Treatment with 1,25(OH)2D3 caused a dose-dependent stimulation of prostate-specific antigen secretion by LNCaP cells. Calcitriol 15-26 kallikrein related peptidase 3 Homo sapiens 66-91